11.11.25 -- How AI Is Rewriting The Future Of TMF And Clinical Quality

Artificial intelligence (AI) and machine learning (ML) hold transformative potential in pharmacovigilance (PV), with the ability to enhance the efficiency, accuracy, and timeliness of drug safety monitoring.

As the next generation of cell-based therapies emerges, see why integrating digital health technologies will be essential for advancing efficacy, safety, and patient experience.

Electronic Medical Record access promises accelerated trials and regulatory-grade evidence, but incomplete, unstructured data requires hybrid strategies using AI and human oversight to bridge gaps.

Rare disease and specialty pharma trials demand a level of flexibility with electronic data capture systems that can adapt dynamically without sacrificing data integrity.

Discover an integrated, 21 CFR Part 11-compliant system designed to enable your staff to easily capture and manage data, facilitate remote workflows, and eliminate duplicative processes.

A combination of industry-leading deidentified lab data, enhanced with claims, prescription (Rx), and EHR insights, allows teams to refine targeting, optimize engagement, and drive better patient outcomes.

See how sponsors of Huntington’s disease (HD) clinical trials can potentially obtain earlier indications of progress by utilizing digital biomarkers.